CLINICAL_TRIALS
trial_result
· 2023-02-09
Clinical Trial Update: Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib
Summary
A retrospective chart review studying patients with PIK3CA-Related Overgrowth Spectrum who received alpelisib; completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS) | Status: COMPLETED | Results posted: 2023-02-09